EU-PFF has set up a Pulmonary Fibrosis Community Advisory Board (PF-CAB) as a working group of the EU-PFF. It comprises a panel of leading European patient advocates who can also call on other international experts. PF-CAB members work together to address issues of strategic importance to the PF community. They advocate for the best possible research and improved and equal access to innovative treatments and are for PF patients. PF-CAB monitors pharmaceutical developments, research and other developments in PF through, long-term cooperation and continued dialogue with pharmaceutical partners, regulators, medical experts, and the scientific PF-community.
The report covers the PF-CAB meeting organised with Boehringer-Ingelheim. You can find it here.
